journal
Journals Journal of Comparative Effecti...

Journal of Comparative Effectiveness Research

https://read.qxmd.com/read/38606574/letter-in-reply-network-meta-analysis-for-indirect-comparison-of-lanadelumab-and-for-the-treatment-of-hereditary-angioedema
#1
JOURNAL ARTICLE
Maureen Watt, Mia Malmenas, Katrin Haeussler
No abstract text is available yet for this article.
April 12, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38606556/polymer-based-drug-eluting-stent-treatment-extends-the-time-to-reintervention-for-patients-with-symptomatic-femoropopliteal-artery-disease-clinical-evidence-and-potential-economic-value
#2
JOURNAL ARTICLE
William A Gray, Yoshimitsu Soga, Masahiko Fujihara, Osamu Iida, Anvar Babaev, Daizo Kawasaki, Thomas Zeller, David O'Connor, Michael R Jaff, Anna M Chavez, Stefan Müller-Hülsbeck
Aim: Use long-term follow-up data from the IMPERIAL study to determine whether drug-eluting polymer-based nitinol stent treatment can delay the time to repeat intervention for femoropopliteal artery disease and how such a delay may result in cost savings in a value-based episode of care. Patients & methods: The IMPERIAL randomized controlled trial was an international study of a paclitaxel-eluting polymer-coated stent (Eluvia, Boston Scientific, MA, USA) versus a polymer-free paclitaxel-coated stent (Zilver PTX, Cook Corporation, IN, USA) for treating lesions of the femoropopliteal arterial segment...
April 12, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38602503/comparing-the-outcomes-and-costs-of-cardiac-monitoring-with-implantable-loop-recorders-and-mobile-cardiac-outpatient-telemetry-following-stroke-using-real-world-evidence
#3
JOURNAL ARTICLE
Vincent Norlock, Reynaldo Vazquez, Alexandria Dunn, Christian Siegfried, Manish Wadhwa, Goran Medic
Aim: Patients with ischemic stroke (IS) commonly undergo monitoring to identify atrial fibrillation with mobile cardiac outpatient telemetry (MCOT) or implantable loop recorders (ILRs). The authors compared readmission, healthcare cost and survival in patients monitored post-stroke with either MCOT or ILR. Materials & methods: The authors used claims data from Optum's de-identified Clinformatics® Data Mart Database to identify patients with IS hospitalized from January 2017 to December 2020 who were prescribed ambulatory cardiac monitoring via MCOT or ILR...
April 11, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38573331/augmenting-external-control-arms-using-bayesian-borrowing-a-case-study-in-first-line-non-small%C3%A2-cell-lung-cancer
#4
JOURNAL ARTICLE
Alessandria Struebing, Chelsea McKibbon, Haoyao Ruan, Emma Mackay, Natalie Dennis, Russanthy Velummailum, Philip He, Yoko Tanaka, Yan Xiong, Aaron Springford, Mats Rosenlund
Aim: This study aimed to improve comparative effectiveness estimates and discuss challenges encountered through the application of Bayesian borrowing (BB) methods to augment an external control arm (ECA) constructed from real-world data (RWD) using historical clinical trial data in first-line non-small-cell lung cancer (NSCLC). Materials & methods: An ECA for a randomized controlled trial (RCT) in first-line NSCLC was constructed using ConcertAI Patient360™ to assess chemotherapy with or without cetuximab, in the bevacizumab-inappropriate subpopulation...
April 4, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38567966/assessing-the-performance-of-physician-s-prescribing-preference-as-an-instrumental-variable-in-comparative-effectiveness-research-with-moderate-and-small-sample-sizes-a-simulation-study
#5
JOURNAL ARTICLE
Lisong Zhang, Jim Lewsey, David A McAllister
Aim: This simulation study is to assess the utility of physician's prescribing preference (PPP) as an instrumental variable for moderate and smaller sample sizes. Materials & methods: We designed a simulation study to imitate a comparative effectiveness research under different sample sizes. We compare the performance of instrumental variable (IV) and non-IV approaches using two-stage least squares (2SLS) and ordinary least squares (OLS) methods, respectively. Further, we test the performance of different forms of proxies for PPP as an IV...
April 3, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38567965/comparing-the-performance-of-two-stage-residual-inclusion-methods-when-using-physician-s-prescribing-preference-as-an-instrumental-variable-unmeasured-confounding-and-noncollapsibility
#6
JOURNAL ARTICLE
Lisong Zhang, Jim Lewsey
Aim: The first objective is to compare the performance of two-stage residual inclusion (2SRI), two-stage least square (2SLS) with the multivariable generalized linear model (GLM) in terms of the reducing unmeasured confounding bias. The second objective is to demonstrate the ability of 2SRI and 2SPS in alleviating unmeasured confounding when noncollapsibility exists. Materials & methods: This study comprises a simulation study and an empirical example from a real-world UK population health dataset (Clinical Practice Research Datalink)...
April 3, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38567953/the-impact-of-willingness-to-pay-threshold-on-price-reduction-recommendations-for-oncology-drugs-a-review-of-assessments-conducted-by-the-canadian-agency-for-drugs-and-technologies-in-health
#7
REVIEW
Chakrapani Balijepalli, Lakshmi Gullapalli, Juhi Joshy, Nigel Sb Rawson
Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold is hypothesized to have a higher impact on the time to access these drugs in Canada. We studied the impact of price reductions on time to engagement and negotiation with the pan-Canadian Pharmaceutical Alliance for oncology drugs reviewed by CADTH between January 2020 and December 2022...
April 3, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38546012/r-we-ready-for-reimbursement-a-round-up-of-developments-in-real-world-evidence-relating-to-health-technology-assessment-part-15
#8
JOURNAL ARTICLE
Alejandra Castanon, Benjamin D Bray, Sreeram V Ramagopalan
In this latest update we discuss real-world evidence (RWE) guidance from the leading oncology professional societies, the American Society of Clinical Oncology and the European Society for Medical Oncology, and the PRINCIPLED practical guide on the design and analysis of causal RWE studies.
March 28, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38545965/letter-to-the-editor-network-meta-analysis-for-indirect-comparison-of-lanadelumab-and-for-the-treatment-of-hereditary-angioedema
#9
LETTER
Max Schlueter, Sandra Nestler-Parr
No abstract text is available yet for this article.
March 28, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38517149/digital-variance-angiography-in-patients-undergoing-lower-limb-arterial-recanalization-cost-effectiveness-analysis-within-the-english-healthcare-setting
#10
JOURNAL ARTICLE
Amir Ansaripour, Eoin Moloney, Michael Branagan-Harris, Lorenzo Patrone, Mehdi Javanbakht
Aim: Digital variance angiography (DVA) is a recently developed image processing method capable of improving image quality compared with the traditionally used digital subtraction angiography (DSA), among patients undergoing lower limb x-ray angiography. This study aims to explore the potential cost-effectiveness of DVA from an English National Health Service perspective. Materials & methods: A two-part economic model, consisting of a decision tree and a Markov model, was developed to consider the costs and health outcomes associated with the use of DVA as part of current practice imaging, compared with x-ray angiography using standard DSA...
March 22, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38497192/gastrointestinal-adverse-effects-associated-with-the-use-of-intravenous-oliceridine-compared-with-intravenous-hydromorphone-or-fentanyl-in-acute-pain-management-utilizing-adjusted-indirect-treatment-comparison-methods
#11
JOURNAL ARTICLE
Joseph Biskupiak, Gary Oderda, Diana Brixner, Todd L Wandstrat
Background: In the absence of head-to-head comparative data from randomized controlled trials, indirect treatment comparisons (ITCs) may be used to compare the relative effects of treatments versus a common comparator (either placebo or active treatment). For acute pain management, the effects of oliceridine have been compared in clinical trials to morphine but not to fentanyl or hydromorphone. Aim: To assess the comparative safety (specifically differences in the incidence of nausea, vomiting and opioid-induced respiratory depression [OIRD]) between oliceridine and relevant comparators (fentanyl and hydromorphone) through ITC analysis...
March 18, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38488048/understanding-economic-analysis-and-cost-effectiveness-of-ct-scan-guided-3-dimensional-robotic-arm-assisted-lower-extremity-arthroplasty-a-systematic-review
#12
REVIEW
Kara Sarrel, Daniel Hameed, Jeremy Dubin, Michael A Mont, David J Jacofsky, Andréa B Coppolecchia
Aim: The overall goal of this review was to examine the cost-utility of robotic-arm assisted surgery versus manual surgery. Methods: We performed a systematic review of all health economic studies that compared CT-based robotic-arm assisted unicompartmental knee arthroplasty, total knee arthroplasty and total hip arthroplasty with manual techniques. The papers selected focused on various cost-utility measures. In addition, where appropriate, secondary aims encompassed various clinical outcomes (e.g., readmissions, discharges to subacute care, etc...
March 15, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38420658/treatment-of-patients-hospitalized-for-covid-19-with-remdesivir-is-associated-with-lower-likelihood-of-30-day-readmission-a-retrospective-observational-study
#13
JOURNAL ARTICLE
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas Oppelt, Mark Berry, Alpesh N Amin
Aim: This observational study investigated the association between remdesivir treatment during hospitalization for COVID-19 and 30-day COVID-19-related and all-cause readmission across different variants time periods. Patients & methods: Hospitalization records for adult patients discharged from a COVID-19 hospitalization between 1 May 2020 to 30 April 2022 were extracted from the US PINC AI Healthcare Database. Likelihood of 30-day readmission was compared among remdesivir-treated and nonremdesivir-treated patients using multivariable logistic regression models adjusted for age, corticosteroid treatment, Charlson comorbidity index and intensive care unit stay during the COVID-19 hospitalization...
February 29, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38415342/use-of-interrupted-time-series-analyses-in-evaluating-health-economic-outcomes-following-implementation-of-multilayer-water-tight-wound-closure-in-a-primary-total-joint-arthroplasty-population
#14
JOURNAL ARTICLE
Ziyu Tan, Joerg Tomaszewski, Brian Po-Han Chen, Najmuddin J Gunja, Katherine Etter
Aim: Total joint arthroplasty (TJA) with multi-layer, watertight closure (MLWC) using knotless barbed suture and 2-octyl cyanoacrylate plus polymer mesh tape was compared with conventional closure (CC) using Vicryl™ sutures and staples. Patients & methods: Electronic medical records of patients undergoing TJA (1574: total knee arthroplasty; 580: total hip arthroplasty; 13: unknown) from a single surgeon at a US hospital (CC 2011 to 2013; MLWC 2015 to 2020) were reviewed. Outcomes were length of stay (LOS), discharge to skilled nursing facility (SNF), 90-day surgical site infection (SSI) and 90-day readmission...
February 28, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38415341/early-stage-hepatocellular-carcinoma-screening-in-patients-with-chronic-hepatitis-b-in-china-a-cost-effectiveness-analysis
#15
JOURNAL ARTICLE
Yuemin Nan, Osvaldo Ulises Garay, Xianzhong Lu, Yue Zhang, Li Xie, Zhongyi Niu, Wen Chen
Aim: To evaluate the cost-effectiveness of seven screening strategies for chronic hepatitis B (CHB) patients in China. Methods: A discrete event simulation model combining a decision tree and Markov structure was developed to simulate a CHB cohort aged ≥40 years on a lifetime horizon and evaluate the costs and health outcomes (quality-adjusted life years [QALYs] gained) of ultrasonography (US), alpha-fetoprotein (AFP), protein induced by vitamin K absence-II (PIVKA-II), AFP+US, AFP+PIVKA-II, GAAD (a diagnostic algorithm based on gender and age combined with results of AFP and PIVKA-II) and GAAD+US...
February 28, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38389409/peg-hydrogel-sealant-versus-fibrin-glue-in-posterior-fossa-surgery-an-economic-comparison-across-five-european-countries
#16
JOURNAL ARTICLE
Giuseppe Talamonti, Jörn-Andre Horaczek, Rafael Torrejon Torres, Lisa Da Deppo, Marissa J Carter
Aim: Posterior cranial fossa (PCF) surgery is associated with complications, including cerebrospinal fluid (CSF) leakage. Dural sealants such as polyethylene glycol (PEG)-based hydrogels and fibrin glue can prevent CSF leaks, with evidence suggesting PEG hydrogels may outperform fibrin glue. However, the budget impact of using PEG hydrogels in PCF surgeries in Europe is unclear. Materials & methods: A decision tree was developed based on a previous US model, to assess the budget impact of switching from fibrin glue to PEG hydrogel in PCF surgery across five European countries...
February 23, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38348827/study-protocol-for-the-social-interventions-for-support-during-treatment-for-endometrial-cancer-and-recurrence-sister-study-a-community-engaged-national-randomized-trial
#17
REVIEW
Ann Oluloro, Bryan Comstock, Sarah E Monsell, Maya Gross, Erika M Wolff, Liz Sage, Julianna Alson, Danielle C Lavallee, Bridgette Hempstead, Adrienne Moore, Ronit Katz, Kemi M Doll
Aim: Social isolation in cancer patients is correlated with prognosis and is a potential mediator of treatment completion. Black women with endometrial cancer (EC) are at increased risk for social isolation when compared with White patients. We developed the Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence (SISTER) study to compare and evaluate interventions to address social isolation among Black women with high-risk EC in USA. The primary objective of the SISTER study is to determine whether virtual support interventions improve treatment completion compared with Enhanced Usual Care...
February 13, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38348818/real-world-data-analysis-of-bilayered-living-cellular-construct-and-fetal-bovine-collagen-dressing-treatment-for-pressure-injuries-a-comparative-effectiveness-study
#18
JOURNAL ARTICLE
Michael L Sabolinski, Tad Archambault
Aim: To determine the effectiveness of bilayered living cellular construct (BLCC) versus a fetal bovine collagen dressing (FBCD) in pressure injuries (PRIs). Methods: A real-world data study was conducted on 1352 PRIs analyzed digitally. 1046 and 306 PRIs were treated with BLCC and FBCD, respectively. Results: Cox healing for BLCC (n = 1046) was significantly greater (p < 0.0001) at week 4 (13 vs 7%), 8 (29 vs 17%), 12 (42 vs 27%), 24 (64 vs 45%), and 36 (73 vs 56%). The probability of healing increased by 66%, (hazard ratio = 1...
February 13, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38329446/access-in-all-areas-a-round-up-of-developments-in-market-access-and-health-technology-assessment-part-3
#19
JOURNAL ARTICLE
Alice Beattie, Catrin Treharne, Sreeram V Ramagopalan
In this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.
February 8, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38329429/acceptability-and-consumers-willingness-to-pay-for-comprehensive-medication-management-services-in-brazil
#20
JOURNAL ARTICLE
Lucas Lima Tôrres, Pâmela Santos Azevedo, Túlio Tadeu Rocha Sarmento, Djenane Ramalho-de-Oliveira, Edna Afonso Reis, Isabella Piassi Dias Godói, Augusto Afonso Guerra Júnior, Cristina Mariano Ruas
Aim: Comprehensive medication management (CMM) is a clinical service that aims to optimize the therapeutic results of patients at the individual level. Studies carried out in Brazil and in several parts of the world have found a positive impact of the service, mainly in the resolution of drug therapy problems and in improving clinical outcomes and patients' quality of life. This service is not widespread and its acceptability and willingness to pay were not defined by the population yet. Objective: This work aims to conduct a study with users of private health services to determine the acceptability and willingness to pay for CMM services...
February 8, 2024: Journal of Comparative Effectiveness Research
journal
journal
43925
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.